ZA97400B - Valaciclovir. - Google Patents

Valaciclovir.

Info

Publication number: ZA97400B
Authority: ZA; South Africa
Prior art keywords: valaciclovir; pharmaceutically acceptable; acceptable salt; genital herpes; suppression
Prior art date: 1996-01-19

Application number

ZA9700400A

Other languages

English (en)

Inventor

John Delehanty

Margaret L Smiley

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-19

Filing date

1997-01-17

Publication date

1997-11-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24399659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA97400(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-01-17 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1997-11-13 Publication of ZA97400B publication Critical patent/ZA97400B/xx

Links

HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 title abstract 6
229940093257 valacyclovir Drugs 0.000 title abstract 6
208000001688 Herpes Genitalis Diseases 0.000 abstract 4
201000004946 genital herpes Diseases 0.000 abstract 4
150000003839 salts Chemical class 0.000 abstract 4
230000001629 suppression Effects 0.000 abstract 3
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 abstract 2
239000002552 dosage form Substances 0.000 abstract 2
230000000306 recurrent effect Effects 0.000 abstract 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
229960004150 aciclovir Drugs 0.000 abstract 1
239000003443 antiviral agent Substances 0.000 abstract 1
239000002775 capsule Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000004474 valine Substances 0.000 abstract 1
-1 valine ester Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA9700400A 1996-01-19 1997-01-17 Valaciclovir. ZA97400B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US59944896A	1996-01-19	1996-01-19

Publications (1)

Publication Number	Publication Date
ZA97400B true ZA97400B (en)	1997-11-13

Family

ID=24399659

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9700400A ZA97400B (en)	1996-01-19	1997-01-17	Valaciclovir.

Country Status (12)

Country	Link
EP (1)	EP0874631B1 (fr)
JP (1)	JP4097698B2 (fr)
AT (1)	ATE254463T1 (fr)
AU (1)	AU722304B2 (fr)
CA (1)	CA2243237C (fr)
CY (1)	CY2512B1 (fr)
DE (1)	DE69726255T2 (fr)
DK (1)	DK0874631T3 (fr)
ES (1)	ES2210490T3 (fr)
PT (1)	PT874631E (fr)
WO (1)	WO1997025989A1 (fr)
ZA (1)	ZA97400B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0010446D0 (en) *	2000-04-28	2000-06-14	Glaxo Wellcome Kk	Pharmaceutical formulation
ITMI20010009A1 (it) *	2001-01-03	2002-07-03	Menarini Ricerche Spa	Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera
HUP0500753A3 (en) *	2001-09-07	2006-05-29	Teva Pharma	Crystalline forms of valacyclovir hydrochloride
MX242714B (es) *	2001-11-14	2006-12-15	Teva Pharma	Sintesis y purificacion de valaciclovir.
US7229644B2 (en) *	2002-05-23	2007-06-12	Cephalon, Inc.	Pharmaceutical formulations of modafinil
AU2003240213A1 (en) *	2002-06-24	2004-01-06	Ranbaxy Laboratories Limited	Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20040116532A1 (en) *	2002-09-13	2004-06-17	Craig Heacock	Pharmaceutical formulations of modafinil
EP1633753A1 (fr) *	2003-05-30	2006-03-15	EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S.	Nouvelles formes cristallines de chlorhydrate de valacyclovir
CN1331471C (zh) *	2003-09-22	2007-08-15	陈云芳	盐酸万乃洛韦软胶囊组合物
WO2007090595A1 (fr) *	2006-02-06	2007-08-16	Fidia Pharmaceutici S.P.A.	Formulations solides de chlorhydrate de valacyclovir
GB0605344D0 (en) *	2006-03-17	2006-04-26	Pliva Istrazivanje I Razvoj D	Pharmaceutically acceptable salts and polymorphic forms
JP4669804B2 (ja) *	2006-03-28	2011-04-13	株式会社オーディオテクニカ	コンデンサマイクロホン
CN1903854B (zh) *	2006-08-09	2012-05-23	丽珠医药集团股份有限公司	一种合成盐酸伐昔洛韦的方法
JPWO2009031576A1 (ja) *	2007-09-03	2010-12-16	味の素株式会社	バラシクロビル塩酸塩結晶の製造方法
CN104188928B (zh) *	2014-09-17	2017-07-28	山东新时代药业有限公司	一种盐酸伐昔洛韦片剂及其制备方法
WO2020049536A1 (fr) *	2018-09-07	2020-03-12	Jubilant Generics Limited	Compositions pharmaceutiques de valacyclovir ou de ses sels pharmaceutiquement acceptables
CN109651371B (zh) *	2018-12-31	2021-02-23	辰欣药业股份有限公司	一种盐酸伐昔洛韦的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AP55A (en) *	1987-08-15	1989-09-26	The Wellcome Foundation Ltd	Therapeutic Acyclic Nucleosides
GB9320316D0 (en) *	1993-10-01	1993-11-17	Smithkline Beecham Plc	Pharmaceuticals
GB9501127D0 (en) *	1995-01-20	1995-03-08	Wellcome Found	Tablet
GB9501178D0 (en) *	1995-01-20	1995-03-08	Wellcome Found	Guanine derivative

1997
- 1997-01-17 WO PCT/EP1997/000192 patent/WO1997025989A1/fr not_active Ceased
- 1997-01-17 ZA ZA9700400A patent/ZA97400B/xx unknown
- 1997-01-17 PT PT97901052T patent/PT874631E/pt unknown
- 1997-01-17 CA CA002243237A patent/CA2243237C/fr not_active Expired - Fee Related
- 1997-01-17 DE DE69726255T patent/DE69726255T2/de not_active Expired - Lifetime
- 1997-01-17 DK DK97901052T patent/DK0874631T3/da active
- 1997-01-17 ES ES97901052T patent/ES2210490T3/es not_active Expired - Lifetime
- 1997-01-17 EP EP97901052A patent/EP0874631B1/fr not_active Revoked
- 1997-01-17 AT AT97901052T patent/ATE254463T1/de not_active IP Right Cessation
- 1997-01-17 AU AU14434/97A patent/AU722304B2/en not_active Ceased
- 1997-01-17 JP JP52569197A patent/JP4097698B2/ja not_active Expired - Fee Related
2005
- 2005-04-18 CY CY0500026A patent/CY2512B1/xx unknown

Also Published As

Publication number	Publication date
CA2243237A1 (fr)	1997-07-24
PT874631E (pt)	2004-04-30
WO1997025989A1 (fr)	1997-07-24
ATE254463T1 (de)	2003-12-15
DE69726255D1 (de)	2003-12-24
JP4097698B2 (ja)	2008-06-11
ES2210490T3 (es)	2004-07-01
CA2243237C (fr)	2008-09-02
DE69726255T2 (de)	2004-08-26
EP0874631A1 (fr)	1998-11-04
EP0874631B1 (fr)	2003-11-19
DK0874631T3 (da)	2004-03-22
AU722304B2 (en)	2000-07-27
CY2512B1 (en)	2005-12-23
AU1443497A (en)	1997-08-11
JP2000503310A (ja)	2000-03-21

Similar Documents

Publication	Publication Date	Title
ZA97400B (en)	1997-11-13	Valaciclovir.
NZ508526A (en)	2004-12-24	Opioid formulations for treating pain
RU2000111506A (ru)	2002-05-10	Таблетки с пролонгированным выделением для лечения болезни паркинсона
UA40589C2 (uk)	2001-08-15	Спосіб лікування людини, що страждає від вірусної інфекції, фармацевтична композиція, комбінація речовин для отримання ліків та фармацевтична комбінація
CA2264852A1 (fr)	1998-04-09	Utilisation de methylphenidate ou d'un sel pharmaceutique acceptable correspondant
JPH06102622B2 (ja)	1994-12-14	肥満の治療
CA2112679A1 (fr)	1993-03-04	Forme pharmaceutique pour la liberation rapide d'un medicament
KR950031069A (ko)	1995-12-18	골손실의 억제 및 혈청 콜레스테롤의 강하 방법
CA2098738A1 (fr)	1993-05-28	Compositions d'oxycodone a degagement progressif
US4438138A (en)	1984-03-20	Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
CA2795038C (fr)	2016-05-17	Antagoniste du recepteur d'opioides (naltrexone) destine a etre utilise pour traiter le zona
CA2180178A1 (fr)	1995-07-06	Utilisation des derives 2,3-diaryl-1-benzopyrane dans la production d'un medicament employe dans le traitement et la prevention de la diminution du volume du tissu osseux et de l'osteoporose
PT1027053E (pt)	2004-09-30	Metodo de prevencao de nefrotoxicidade provocada por ciclosporinas e tacrolimus
CA2294281A1 (fr)	1998-12-23	Procede de traitement du syndrome de la fatigue chronique et de la fibromyalgie par la buprenorphine
MY124465A (en)	2006-06-30	Reduction of infarct volume using citicoline
JPH08283148A (ja)	1996-10-29	うつ性症状改善剤
NO974486L (no)	1997-09-29	Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
WO1992015315A1 (fr)	1992-09-17	Mode de traitement de l'herpes
RU99112967A (ru)	2001-04-27	Способ лечения и профилактики дизентерии свиней
HU211305A9 (en)	1995-11-28	Novel method for treatment of parkinson's disease
JPH0680564A (ja)	1994-03-22	抗色素沈着治療薬
AR020167A1 (es)	2002-04-10	Metodo para la prevencion del inicio del asma
JP4344532B2 (ja)	2009-10-14	鼻炎用組成物
WO2014024195A1 (fr)	2014-02-13	Ligands du récepteur a3 de l'adénosine pour l'utilisation dans le traitement d'un dysfonctionnement sexuel
JP2004026810A (ja)	2004-01-29	鼻炎用組成物